ArticleDiscover oncology2025
Prognostic role and tumor-suppressive effects of CADM family members and the potential molecular mechanisms of CADM1 in neuroblastoma.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundThe exact role of cell adhesion molecule (CADM) family members in neuroblastoma is still being explored. Here we uncovered the survival association and the possible mechanisms of CADMs in neuroblastoma through comprehensive bioinformatic analyses. Then the results of CADM1 were verified in neuroblastoma cell lines.
methodsCADMs expression was examined by cBioPortal and TARGET databases and verified in several GEO datasets. Kaplan-Meier plot, log-rank test, the ROC curve, and Cox regression analysis were utilized to assess the prognostic value of CADMs in neuroblastoma. Through functional enrichment analysis and interaction network construction, hub genes were screened to explore the molecular mechanism of CADMs in neuroblastoma. We tested the abilities of cell growth and migration in neuroblastoma cells when CADM1 was silenced and overexpressed respectively. We then used western blot to verify the phosphorylation levels of AKT/GSK-3β pathways.
resultsThe expression of CADM1-4 was significantly down-regulated in neuroblastoma patients with unfavorable prognostic factors. Moreover, CADM1 and CADM3 increased the accuracy of classical clinical indicators for predicting survival rate. The top 10 KEGG pathways for CADMs and their co-expression genes were mainly enriched in the mitotic cell cycle and the process of chromosomal duplication. Furthermore, our study showed that CADM1 inhibited neuroblastoma cells proliferation, migration and the phosphorylation of GSK-3β.
conclusionsDecreased expression of CADM1 and CADM3 was significantly associated with poor outcomes in neuroblastoma. CADM1 may suppress neuroblastoma cell proliferation and migration through regulating the phosphorylation of GSK-3β.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.